Literature DB >> 20927303

Psychopharmacological treatment status in outpatients with bipolar disorder: a clinical survey in Germany.

Arnim Quante1, Sara Zeugmann, Francesca Regen, Annette Engelhardt, Ion-George Anghelescu.   

Abstract

OBJECTIVE: The objective of this epidemiological study was to evaluate the current treatment status as well as the acceptance of medication and satisfaction with life in outpatients with bipolar disorder in Germany.
METHODS: Data for this cross-sectional epidemiologic survey was collected between February 15th, 2006 and May 31st, 2006. Three hundreds six bipolar euthymic outpatients under routine treatment conditions were included in the study. Forty one practicing psychiatrists used a clinical interview to evaluate the current treatment status, acceptance of current medication, and current life satisfaction.
RESULTS: The majority of patients suffered from "pure" bipolar-II-disorder (50.6%), followed by 23.0% with "pure" bipolar-I-disorder. Apart from these patients, 12.9% of all participants had a history of mixed episodes and 5.6% a history of rapid cycling. Mean duration of bipolar disorder was 10.6 years. The majority of patients (54.3%) received psychopharmacological monotherapy. Combination therapy was administered in 45.9% of the patients, 39.3% receiving two agents, and 6.6% three agents. Antidepressants (64.1%) were the most common combination medications. Monotherapy was used preferably in bipolar-I- (62.7%) and bipolar-II-disorders (56.2%), combination therapy predominantly in patients with a history of mixed episodes (57.7%) and rapid cycling (55.0%). Half of the patients (49.2%) were able to hold an occupation. 84.2% of all patients were satisfied with their medication. Overall, patients evaluated their life satisfaction between "good" and "satisfactory" (2.69 according to German school grades where 1 is the highest and 6 the lowest mark). Patients receiving lithium, valproate or antidepressants as monotherapy rated above the mean, patients with combination therapy, carbamazepine monotherapy or medications summarized as "others" rated below the mean.
CONCLUSION: Most of the German outpatients received a pharmacotherapy that is recommended in the guidelines of bipolar disorder. The use of (atypical) antipsychotics was low. Conversely, the incidence of treatment with tricyclic antidepressants (not guideline compatible), was observed to be relatively high. Irrespective of their medication, in Germany patients with bipolar disorder show a high acceptance of their pharmacotherapy, and rate their life satisfaction as high. Nonetheless, half of the evaluated patients were not able to pursue a profession. Besides the disease age, gender and family life e.g., child care may also play a confounding role regarding the unemployment statistics.

Entities:  

Keywords:  Bipolar disorder; Mania; Pharmacotherapy; Quality of life

Year:  2010        PMID: 20927303      PMCID: PMC2947802          DOI: 10.4306/pi.2010.7.3.155

Source DB:  PubMed          Journal:  Psychiatry Investig        ISSN: 1738-3684            Impact factor:   2.505


  27 in total

1.  Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population.

Authors:  Michael Eaddy; Amy Grogg; Julie Locklear
Journal:  Clin Ther       Date:  2005-02       Impact factor: 3.393

2.  A double-blind comparison of valproate and lithium in the treatment of acute mania.

Authors:  T W Freeman; J L Clothier; P Pazzaglia; M D Lesem; A C Swann
Journal:  Am J Psychiatry       Date:  1992-01       Impact factor: 18.112

3.  Changes in the quality of care for bipolar I disorder during the 1990s.

Authors:  Alisa B Busch; Davina Ling; Richard G Frank; Shelly F Greenfield
Journal:  Psychiatr Serv       Date:  2007-01       Impact factor: 3.084

4.  Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features.

Authors:  M Tohen; J Hennen; C M Zarate; R J Baldessarini; S M Strakowski; A L Stoll; G L Faedda; T Suppes; P Gebre-Medhin; B M Cohen
Journal:  Am J Psychiatry       Date:  2000-02       Impact factor: 18.112

5.  Historical perspectives and natural history of bipolar disorder.

Authors:  J Angst; R Sellaro
Journal:  Biol Psychiatry       Date:  2000-09-15       Impact factor: 13.382

6.  Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.

Authors:  Gabriele S Leverich; Lori L Altshuler; Mark A Frye; Trisha Suppes; Susan L McElroy; Paul E Keck; Ralph W Kupka; Kirk D Denicoff; Willem A Nolen; Heinz Grunze; Maria I Martinez; Robert M Post
Journal:  Am J Psychiatry       Date:  2006-02       Impact factor: 18.112

7.  Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Claire O'Donovan; Sagar V Parikh; Glenda MacQueen; Roger S McIntyre; Verinder Sharma; Serge Beaulieu
Journal:  Bipolar Disord       Date:  2006-12       Impact factor: 6.744

8.  Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder.

Authors:  Frank D Gianfrancesco; Martha Sajatovic; Krithika Rajagopalan; Ruey-Hua Wang
Journal:  Clin Ther       Date:  2008-07       Impact factor: 3.393

Review 9.  Enhancing treatment with psychotropic medicines.

Authors:  R J Baldessarini
Journal:  Bull Menninger Clin       Date:  1994

10.  Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder.

Authors:  Ralph W Kupka; Lori L Altshuler; Willem A Nolen; Trisha Suppes; David A Luckenbaugh; Gabriele S Leverich; Mark A Frye; Paul E Keck; Susan L McElroy; Heinz Grunze; Robert M Post
Journal:  Bipolar Disord       Date:  2007-08       Impact factor: 6.744

View more
  4 in total

Review 1.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

2.  Antidepressant dosage taken by patients with bipolar disorder: factors associated with irregularity.

Authors:  Rita Bauer; Tasha Glenn; Martin Alda; Kemal Sagduyu; Wendy Marsh; Paul Grof; Rodrigo Munoz; Greg Murray; Philipp Ritter; Ute Lewitzka; Emanuel Severus; Peter C Whybrow; Michael Bauer
Journal:  Int J Bipolar Disord       Date:  2013-12-09

3.  Drug treatment patterns in bipolar disorder: analysis of long-term self-reported data.

Authors:  Michael Bauer; Tasha Glenn; Martin Alda; Kemal Sagduyu; Wendy Marsh; Paul Grof; Rodrigo Munoz; Emanuel Severus; Philipp Ritter; Peter C Whybrow
Journal:  Int J Bipolar Disord       Date:  2013-05-03

Review 4.  Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review.

Authors:  Michele Fornaro; Domenico De Berardis; Ann Sarah Koshy; Giampaolo Perna; Alessandro Valchera; Davy Vancampfort; Brendon Stubbs
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-31       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.